Cargando…
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
BACKGROUND: Long-acting injectable (LAI) antipsychotics use is associated with improved adherence which can reduce the rate of relapse, hospitalization, and associated costs in patients with schizophrenia. Young adults could be at higher risk of poor adherence, hence use of LAI in this population ma...
Autores principales: | Fu, Alex Z., Pesa, Jacqueline A., Lakey, Susan, Benson, Carmela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994268/ https://www.ncbi.nlm.nih.gov/pubmed/35395757 http://dx.doi.org/10.1186/s12888-022-03895-2 |
Ejemplares similares
-
Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015) -
Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
por: Kamat, Siddhesh A, et al.
Publicado: (2015) -
The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023) -
Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database
por: Pesa, Jacqueline, et al.
Publicado: (2022) -
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)